A 28-year-old woman with systemic lupus erythematosus develops fever, rash, arthralgia, and lymphadenopathy 2 weeks after starting phenytoin for seizure prophylaxis. Laboratory tests show eosinophilia (8%), atypical lymphocytes, and elevated liver enzymes (AST 180 U/L, ALT 220 U/L). What is the most appropriate immediate next step?

Explanation

## Clinical Context This patient presents with **Aromatic Antiepileptic Drug (AAD) Hypersensitivity Syndrome** — a severe **Type B (Bizarre) Adverse Drug Reaction** characterized by fever, rash, lymphadenopathy, hepatitis, and hematologic abnormalities occurring 2–8 weeks after drug initiation. ## Type B vs Type A ADR Comparison | Feature | Type A (Augmented) | Type B (Bizarre) | |---------|-------------------|------------------| | Mechanism | Dose-dependent, exaggerated pharmacology | Idiosyncratic, immune-mediated | | Predictability | Predictable, common | Unpredictable, rare | | Onset | Dose-related | Independent of dose | | Severity | Mild to moderate | Often severe, life-threatening | | Management | Dose reduction or continuation | **Immediate discontinuation** | | Example | ACE inhibitor cough | Phenytoin hypersensitivity | **Key Point:** Type B reactions are NOT dose-dependent and do NOT improve with dose reduction. Immediate drug discontinuation is mandatory to prevent progression to Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), or organ failure. ## Diagnostic Criteria for AAD Hypersensitivity Syndrome **Mnemonic: FLAHS** — Fever, Lymphadenopathy, Atypical lymphocytes/Eosinophilia, Hepatitis, Systemic involvement 1. **Fever** ✓ (present) 2. **Rash** ✓ (present) 3. **Lymphadenopathy** ✓ (present) 4. **Hematologic abnormalities** ✓ (eosinophilia 8%, atypical lymphocytes) 5. **Hepatitis** ✓ (elevated transaminases) 6. **Timing:** 2–8 weeks post-initiation ✓ (2 weeks) ## Management Algorithm ```mermaid flowchart TD A[Suspected AAD hypersensitivity syndrome]:::outcome --> B{Fever + rash + lymphadenopathy + hepatitis + eosinophilia?}:::decision B -->|Yes| C[IMMEDIATELY discontinue phenytoin]:::urgent C --> D[Supportive care: IV fluids, antipyretics]:::action D --> E[Monitor for SJS/TEN, hepatic failure, hematologic complications]:::action E --> F[Consider systemic corticosteroids if severe cutaneous involvement]:::action B -->|No| G[Investigate alternative diagnosis]:::action ``` **High-Yield:** Aromatic anticonvulsants (phenytoin, carbamazepine, phenobarbital) carry a 1 in 1000–10,000 risk of hypersensitivity syndrome. Non-aromatic alternatives (levetiracetam, lamotrigine, valproate) have lower risk. **Clinical Pearl:** Cross-reactivity between aromatic AADs is 25–80%; therefore, switching to carbamazepine or phenobarbital is contraindicated and risks recurrence of the reaction. **Warning:** Continuing phenytoin or switching to a structurally similar aromatic AAD can lead to progression to SJS/TEN, multi-organ failure, and death. This is a medical emergency. [cite:Harrison 21e Ch 297; KD Tripathi 8e Ch 25]